Effectdossier · gearchiveerd kwartaal
ORIC
ORIC Pharmaceuticals, Inc. · Healthcare · Biotechnology
17Gevolgde houders
0Δ houders
34.78MGehouden aandelen
$417.41MGerapporteerde waarde
+0Nieuwe posities
−0Uitstappen
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +11.4% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 0 | 59.02M | $639.12M | +7 | −7 |
| Q1 2026 | 75 | +3 | 50.35M | $637.44M | +9 | −6 |
| Q4 2025 | 72 | +1 | 55.15M | $451.14M | +1 | — |
| Q3 2025 | 17 | 0 | 34.78M | $417.41M | — | — |
| Q2 2025 | 14 | +1 | 27.12M | $275.30M | +3 | −2 |
| Q1 2025 | 10 | +1 | 12.33M | $68.78M | +2 | −1 |
| Q4 2024 | 9 | -1 | 9.74M | $78.61M | — | −1 |
| Q3 2024 | 9 | 0 | 7.63M | $78.26M | +1 | −1 |
| Q2 2024 | 9 | — | 8.42M | $59.53M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 6.57M | 0.0% | $78.87M | 0.2% | Held | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | BlackRock ✦ (passief) | 5.28M | +29.4% | $63.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passief) | 4.65M | +48.8% | $55.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passief) | 4.65M | +48.8% | $55.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | The Vanguard Group ✦ (passief) | 4.65M | +48.8% | $55.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | The Vanguard Group ✦ (passief) | 4.65M | +48.8% | $55.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | The Vanguard Group ✦ (passief) | 4.65M | +48.8% | $55.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 2.87M | +3.9% | $34.46M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 2.87M | +3.9% | $34.46M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Point72 Asset Management ✦ | 2.62M | -8.1% | $31.44M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 22 | Fidelity (FMR) ✦ | 2.53M | +2.4% | $30.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 23 | Fidelity (FMR) ✦ | 2.53M | +2.4% | $30.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | JPMorgan Chase ✦ | 2.46M | — | $29.48M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | JPMorgan Chase ✦ | 2.46M | — | $29.48M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | JPMorgan Chase ✦ | 2.46M | — | $29.48M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | JPMorgan Chase ✦ | 2.46M | — | $29.48M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 2.46M | — | $29.48M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | JPMorgan Chase ✦ | 2.46M | — | $29.48M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | State Street Global Advisors ✦ (passief) | 2.40M | +47.3% | $28.85M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 31 | Geode Capital Management ✦ (passief) | 1.63M | +47.1% | $19.57M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 32 | Geode Capital Management ✦ (passief) | 1.63M | +47.1% | $19.57M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 33 | Citadel Advisors ✦ | 1.20M | -14.6% | $14.38M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 34 | Goldman Sachs Group ✦ | 904.81K | — | $10.86M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | Goldman Sachs Group ✦ | 904.81K | — | $10.86M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | Morgan Stanley ✦ | 745.53K | — | $8.95M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | Morgan Stanley ✦ | 745.53K | — | $8.95M | 0.0% | n/c | 1 | SEC ↗ |
| 38 | Morgan Stanley ✦ | 745.53K | — | $8.95M | 0.0% | n/c | 1 | SEC ↗ |
| 39 | Morgan Stanley ✦ | 745.53K | — | $8.95M | 0.0% | n/c | 1 | SEC ↗ |
| 40 | Adage Capital Partners ✦ | 447.37K | +22.4% | $5.37M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 41 | AQR Capital Management ✦ | 171.93K | +0.3% | $2.06M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 42 | AQR Capital Management ✦ | 171.93K | +0.3% | $2.06M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 43 | AQR Capital Management ✦ | 171.93K | +0.3% | $2.06M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 44 | AQR Capital Management ✦ | 171.93K | +0.3% | $2.06M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 45 | Wellington Management ✦ | 150.59K | -32.6% | $1.81M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 46 | Wellington Management ✦ | 150.59K | -32.6% | $1.81M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 47 | Wellington Management ✦ | 150.59K | -32.6% | $1.81M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 48 | Millennium Management ✦ | 140.43K | -59.9% | $1.69M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 49 | Renaissance Technologies ✦ | 14.50K | +42.2% | $174,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 181 houders, 119.04M aandelen, $1.43B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API